Synaps Dx's Alzheimer's disease test gets payment code

LabPulse.com staff writers
Nov 8, 2021
2020 03 31 23 03 5810 Brain Dementia Leaves 400

Synaps Dx's Discern test for Alzheimer's disease has received a proprietary laboratory analyses (PLA) code from the American Medical Association for use in submitting insurance claims

The Discern test is the first autopsy-validated, minimally invasive test for the definitive diagnosis of Alzheimer's disease versus other forms of non-Alzheimer's disease dementias to earn PLA codes 206U and 207U, Synaps Dx said.

Research supporting the Discern test has been published in more than 300 peer-reviewed articles, the company said.

PLA codes are alphanumeric CPT codes with a corresponding descriptor for labs or manufacturers to more specifically identify their test. Tests with PLA codes must be performed on human specimens and must be requested by the clinical laboratory or manufacturer that offers the test, Synaps added.

Latest in Alzheimer's
Amyloid Plaque Alzheimer Social
Alzheimer’s drug approval poised to reshape APOE testing market
September 25, 2023
Latest in at-home or lab-based STI testing
Sponsored
Latest in at-home or lab-based STI testing
September 28, 2023
Alzheimers Tau Tangles Social
C2N Diagnostics rolls out second-generation Alzheimer's disease biomarker test
August 29, 2023
Amyloid Plaque Alzheimer Social
Exploratory trial links kinase inhibitor to epigenetic changes in dementia patients
August 22, 2023
Related Stories
Amyloid Plaque Alzheimer2 Social
Alzheimer's
Synaps Dx touts importance of skin sample test given FDA's recent Alzheimer's treatment approval
2021 06 23 21 28 5659 Woman Dementia Alzheimer 400
Alzheimer's
SDx partners with I-Ally on Alzheimer's test
2019 07 15 19 08 6013 Amyloid Plaque Alzheimer 400
Alzheimer's
AAIC update: Where blood-based dementia tests stand in 2019
Latest in at-home or lab-based STI testing
Sponsor Content
Latest in at-home or lab-based STI testing
More in Alzheimer's
Alzheimer’s drug approval poised to reshape APOE testing market
The U.S. Food and Drug Administration (FDA) approval of Biogen and Eisai’s Alzheimer’s disease drug Leqembi is likely to drive changes in the APOE testing market, according to an article in GenomeWeb.
September 25, 2023
Amyloid Plaque Alzheimer Social
Experts raise concerns about Quest Diagnostics’ consumer-initiated Alzheimer’s test
Experts have raised concerns about Quest Diagnostics’ $399 consumer-initiated Alzheimer’s disease test, telling 360Dx that it is unclear whether the product is accurate enough to support its use.
September 15, 2023
Amyloid Plaque Alzheimer2 Social
C2N Diagnostics rolls out second-generation Alzheimer's disease biomarker test
C₂N Diagnostics has unveiled its “next generation” blood biomarker test to evaluate patients with signs and symptoms of Alzheimer’s disease (AD) and other causes of cognitive decline.
August 29, 2023
Alzheimers Tau Tangles Social
Exploratory trial links kinase inhibitor to epigenetic changes in dementia patients
Results from a clinical trial show that a small molecule that binds to kinases involved in inflammatory signaling may induce epigenetic changes in people with mild cognitive impairment and probable Alzheimer’s disease.
August 22, 2023
Amyloid Plaque Alzheimer Social
Quest Diagnostics launches consumer-initiated Alzheimer’s risk assessment test
The new test uses the same technology as Quest's clinical AD-Detect Amyloid Beta 42/40 Ratio biomarker test for assessing amyloid beta protein, a recognized marker for Alzheimer’s, which was made available for physicians in early 2022.
August 1, 2023
Brain Amyloid Plaque Neuron Social
Cumulus Neuroscience partners with U.K. universities on cognition test for early Alzheimer’s diagnosis
The partnership will look to scale the development and testing of the Fastball EEG test, which uses an EEG headset to measure brain activity while patients watch a series of flashing images displayed on a tablet or smartphone screen.
July 25, 2023
Brain Puzzle Dementia Social
DiamiR Biosciences partners with JADBio on diagnostic tests, validation for biomarker panels
Under the deal, DiamiR will apply the capabilities of JADBio’s Automated Machine Learning (AutoML) bioinformatics platform and services to its own microRNA platform.
July 12, 2023
Amyloid Plaque Alzheimer Social
Roche receives FDA clearance for test to accelerate diagnosis of Alzheimer’s
The new 510(k) clearance covers two tests that run on Roche’s Elecsys immunoassay system. One of the assays, which measures beta-amyloid, was part of the 510(k) clearance that Roche received last year.
June 29, 2023
Alzheimers Phases Amyloid Social
Biotech firm AltPep closes $53M Series B financing round
AltPep said that the proceeds from the round will be used to accelerate its Sobin therapeutics for Alzheimer’s and Parkinson’s diseases into phase I clinical trials, as well as to advance its Soba diagnostic blood-based assay for Alzheimer’s disease.
June 23, 2023
Research Money Social
Alzheimer’s and encephalopathy linked to eye biomarkers
Study finds Alzheimer's disease and chronic traumatic encephalopathy cases are linked to biomarkers present in the eye’s vitreous humor.
June 20, 2023
Eye Dna Sight Social
Gut bacteria changes in preclinical Alzheimer’s suggest ways to detect, delay disease
Earlier studies found that the gut microbiomes of people with symptomatic Alzheimer’s differ from those of healthy people of the same age, but were unable to tell how early the divergence begins.
June 14, 2023
Alzheimers Phases Amyloid Social
Blood biomarker in study predicts whether the cognitively healthy will develop Alzheimer’s
Astrocytes -- a subtype of glial cells that make up most cells in the human central nervous system -- may be the key driver of Alzheimer's disease progression, researchers said.
May 30, 2023
Alzheimers Tau Tangles Social
Page 1 of 7
Next Page